Editorial: Innovative approaches to combat tumorigenesis and drug resistance: from molecular insights to therapeutic advancements
Frontiers in Cell and Developmental Biology · 17.11.2026 · 14
DOI: 10.3389/fcell.2026.2051069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 17.11.2026. Verfasst von Zhi Guo. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Malignant tumorigenesis and therapeutic resistance represent two persistent challenges in oncology. Tumor development is not an isolated event, but a multistep, cumulative process driven by genetic mutations, epigenetic remodeling and environmental cues. Genomic instability and dysregulated DNA repair, together with reversible epigenetic alterations,contribute to uncontrolled cell proliferation, evasion of apoptosis, and metastatic potential, ultimatelydriving malignant transformation.Meanwhile, drug resistance may be intrinsic or acquired through clonal evolution under therapeutic pressure. Resistance emerges either de novo or progressively during treatment, severely limiting the efficacy of conventional chemotherapy, targeted therapy and immunotherapy. This phenomenon arises from a tangled set of contributors: tumor heterogeneity, target alteration, activation of compensatory signaling cascades, dynamic remodeling of the tumor microenvironment, and microbiome modulation during cancer therapy. The layered complexity of these mechanisms renders cancer management a formidable clinical and scientific endeavor. This Research Topic aims to dissect the intricate cellular and molecular underpinnings of tumor initiation and resistance. Its core objective is to generate actionable knowledge to guide more precise and potent therapeutic strategies. We seek to unpack the multifaceted roles of the tumor microenvironment, immune responses and epigenetic reprogramming in supporting tumor progression and therapeutic failure, refine treatment algorithms, and deepen our understanding of fecal microbiota transplantation (FMT) within precision oncology. To rigorously address these questions, the topic welcomed submissions across eight thematic axes: molecular mechanisms of tumorigenesis, genetic and epigenetic drivers of resistance, tumor microenvironment, therapeutic innovations, predictive biomarkers, immune evasion and immunotherapy resistance, gut microbiota profiling and predictive modeling, and translational and clinical research of FMT for cancer precision medicine. A total of 15 articles were ultimately accepted for this Research Topic This topic also assembles cutting-edge therapeutic innovations. AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids validates AUM-302, a triple PIM/PI3K/mTOR inhibitor, which exerts synergistic anti-tumor activity together with RAS suppression against pancreatic ductal adenocarcinoma spheroids and organoids. This combinatorial strategy offers a promising direction for RAS-driven, highly heterogeneous pancreatic cancer with limited therapeutic options. Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances summarizes the progress and challenges of FGFR inhibitors for glioma, a refractory primary brain tumor. Sacituzumab govitecan combined with anlotinib in metastatic triple negative breast cancer patient with repeated pleural effusion: a case report presents a clinical case of sacituzumab govitecan plus anlotinib for metastatic triple-negative breast cancer with recurrent pleural effusion, demonstrating the exploratory value of ADC-antiangiogenic combinations in this hard-to-treat subtype. To address delivery barriers such as the blood-brain barrier, 3D-ASC-Exos as a novel drug carrier for glioma treatment develops 3D adipose stem cell-derived exosomes as a novel delivery platform for glioma therapy, offering a new technical route for targeted brain drug delivery.Tumor microenvironment and regulated cell death are another central theme. Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy constructs a framework for the hostile physicochemical niche in bone metastasis, describing how acidic, hypoxic and nutrient-deprived conditions sustain tumor survival and resistance, and outlining niche-tailored therapeutic approaches. Ferroptosis and cuproptosis in head and neck squamous cell carcinoma: interconnected mechanisms and therapeutic implications dissects the interconnected regulatory networks of ferroptosis and cuproptosis, Ferroptosis and cuproptosis are two forms of regulated cell death distinct from apoptosis. Theirpotential roles in addressing apoptosis-related resistance in head and neck squamous cell carcinomaare increasingly attracting attention.The gut microbiome has emerged as a key modifier of oncogenesis. The role of gut microbiota and its metabolites in preventing oncogenesis reviews gut commensals and their metabolites in cancer prevention, covering immune regulation, mucosal barrier integrity and metabolic signaling. These findings provide a theoretical basis for microbiota-directed approaches to cancer prevention andtreatment. In addition, the expanding exploration of FMT in infectiousdiseases, immune-related conditions, and oncology highlights its potential as a complementarystrategy.Reliable biomarkers are indispensable for precision oncology. Integrated machine learning analysis of 30 cell death patterns identifies a novel prognostic signature in glioma leverages machine learning integrating 30 cell death programs to build a novel prognostic signature for glioma, demonstrating the value of computational modeling for risk stratification and individualized treatment.Collectively, these fifteen contributions address the core questions of this Research Topic: how tumors initiate, how resistance evolves, and how therapeutic strategies can be innovated.Mechanistically, the collection advances our understanding of oncogenic drivers, DNA damage repair, ubiquitination-autophagy signaling, novel regulated cell death and microenvironment crosstalk. Translational outputs include multi-target inhibitors, ADC combinations, natural product agents, FGFR blockade and exosome delivery systems, alongside real-world clinical observations and predictive models bridging bench to bedside. Important challenges remain: tumor heterogeneity and dynamic resistance evolution require longitudinal sampling and real-time monitoring; the roles of immune microenvironment and metabolic reprogramming in resistance demand further clarification; high-quality prospective clinical trials are still needed to validate microbiota-based interventions such as FMT. We anticipate that the molecular insights generated within this collection will continue to translate into accessible precision therapies, shifting cancer care from empiric one-size-fits-all regimens to truly individualized management and improving outcomes for patients with cancer.
Zitieren
APA
Guo, Z. (2026). Editorial: Innovative approaches to combat tumorigenesis and drug resistance: from molecular insights to therapeutic advancements. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.2051069
Vancouver
Guo Z. Editorial: Innovative approaches to combat tumorigenesis and drug resistance: from molecular insights to therapeutic advancements. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.2051069
BibTeX
@article{Guo2026,
author = {Guo, Zhi},
title = {Editorial: Innovative approaches to combat tumorigenesis and drug resistance: from molecular insights to therapeutic advancements},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.2051069}
}
EUVIMED